SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
Free Webinar | October 11: How to Break Barriers
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
Don’t Chase American Virtual Cloud Technologies Higher
3 Stocks With Market-Beating Price Performance
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:RXRX

Recursion Pharmaceuticals - RXRX Stock Forecast, Price & News

$11.72
+0.11 (+0.95%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.38
$11.84
50-Day Range
$8.30
$13.60
52-Week Range
$4.92
$21.19
Volume
580,062 shs
Average Volume
1.64 million shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Recursion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
2.4% Upside
$12.00 Price Target
Short Interest
Bearish
17.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.44mentions of Recursion Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.57 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.37) to ($1.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.95 out of 5 stars

Medical Sector

1063rd out of 1,075 stocks

Biological Products, Except Diagnostic Industry

168th out of 170 stocks

RXRX stock logo

About Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXRX Stock News Headlines

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up to $9.97
Recursion Pharmaceuticals: Destination Unknown
Cathie Wood’s Top 10 Buys in July
See More Headlines
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXRX Company Calendar

Last Earnings
8/09/2022
Today
10/07/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXRX
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-186,480,000.00
Net Margins
-1,294.12%
Pretax Margin
-1,294.12%

Debt

Sales & Book Value

Annual Sales
$10.18 million
Book Value
$3.19 per share

Miscellaneous

Free Float
132,777,000
Market Cap
$2.00 billion
Optionable
Not Optionable
Beta
-0.75

Key Executives

  • Dr. Christopher C. Gibson Ph.D. (Age 39)
    Co-Founder, CEO & Director
    Comp: $673.59k
  • Ms. Tina Marriott LarsonMs. Tina Marriott Larson (Age 47)
    COO & Pres
    Comp: $595.95k
  • Dr. Blake C. Borgeson Ph.D. (Age 40)
    Co-Founder & Director
    Comp: $30k
  • Dr. Michael Secora Ph.D. (Age 39)
    Chief Financial Officer
    Comp: $510.34k
  • Dr. Shafique Virani M.D. (Age 51)
    Interim Chief Medical Officer & Chief Bus. Officer
    Comp: $688.17k
  • Kevin Leggat
    VP of Fin. & Accounting
  • Mr. Benjamin Mabey M.S. (Age 39)
    Chief Technology Officer
  • Mr. Jared Allenbach
    Sr. Director of Investor Relations
  • Ms. Louisa Daniels J.D. (Age 64)
    M.B.A., Chief Legal Officer & Gen. Counsel
  • Mr. Ryan Kelly
    Chief Communications Officer













RXRX Stock - Frequently Asked Questions

Should I buy or sell Recursion Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXRX, but not buy additional shares or sell existing shares.
View RXRX analyst ratings
or view top-rated stocks.

What is Recursion Pharmaceuticals' stock price forecast for 2022?

4 brokerages have issued 1 year price targets for Recursion Pharmaceuticals' stock. Their RXRX share price forecasts range from $8.00 to $20.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for RXRX
or view top-rated stocks among Wall Street analysts.

How have RXRX shares performed in 2022?

Recursion Pharmaceuticals' stock was trading at $17.13 at the beginning of the year. Since then, RXRX shares have decreased by 31.6% and is now trading at $11.72.
View the best growth stocks for 2022 here
.

When is Recursion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our RXRX earnings forecast
.

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) issued its earnings results on Tuesday, August, 9th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.03. The company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $5.60 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 45.13% and a negative net margin of 1,294.12%.

When did Recursion Pharmaceuticals IPO?

(RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets acted as the underwriters for the IPO.

What is Recursion Pharmaceuticals' stock symbol?

Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX."

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Recursion Pharmaceuticals' stock price today?

One share of RXRX stock can currently be purchased for approximately $11.72.

How much money does Recursion Pharmaceuticals make?

Recursion Pharmaceuticals (NASDAQ:RXRX) has a market capitalization of $2.00 billion and generates $10.18 million in revenue each year. The company earns $-186,480,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Recursion Pharmaceuticals have?

The company employs 400 workers across the globe.

How can I contact Recursion Pharmaceuticals?

Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The official website for the company is www.recursion.com. The company can be reached via phone at 385-269-0203, via email at investorrelations@recursion.com, or via fax at 801-821-2872.

This page (NASDAQ:RXRX) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.